Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer

Cancer Chemotherapy and Pharmacology
Edgardo RiveraGabriel N Hortobagyi

Abstract

We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil. Patients with metastatic breast cancer were eligible if they had disease progression while receiving an anthracycline-containing regimen or developed evidence of metastatic disease during or within 6 months after the last cycle of an anthracycline-containing adjuvant regimen. Prior treatment with liposomal doxorubicin was not allowed. Patients received a dose of 50 mg/m(2) infused every 4 weeks via a peripheral vein or central line. Doxil was administered for a total of six cycles or until disease progression. We treated 11 patients with stage IV breast cancer of whom two had never received chemotherapy for their metastatic disease. Most had a performance status of 1 and had visceral involvement as their dominant site of disease. All patients had received prior therapy with doxorubicin. No clinical evidence of congestive heart failure or cardiac toxicity was observed. The most common toxicities were nonhematologic and were mostly grade 1/2. These included fatigue, nausea, vomiting, and stomati...Continue Reading

Citations

May 24, 2006·Cancer Chemotherapy and Pharmacology·Alexandros ArdavanisUNKNOWN Breast Cancer Committee of the Hellenic Oncology Research Group
Dec 4, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Christoph MamotJohn W Park
Nov 1, 2002·Current Opinion in Oncology·Antonio C Wolff
Jun 10, 2010·Nanomedicine·Xiaowei Dong, Russell J Mumper
Aug 24, 2010·Journal of Ethnopharmacology·Rui Zhi ZhaoYing Zhao
Jul 15, 2009·Clinical Breast Cancer·Conleth G Murphy, Andrew D Seidman
Nov 19, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dandan LuoJonathan F Lovell
Feb 19, 2005·Seminars in Oncology·David S AlbertsAlberto A Gabizon
Oct 19, 2004·Seminars in Oncology·Robert LeonardChris Twelves
Sep 10, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ann L B SeynhaeveTimo L M Ten Hagen
Feb 15, 2002·Clinical Journal of Oncology Nursing·Kathy Wilkinson
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edgardo RiveraGabriel N Hortobagyi
Jan 21, 2017·Advanced Science·Dandan LuoJonathan F Lovell
Aug 14, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Dunja SobotPatrick Couvreur
Sep 1, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Marzieh MohammadiMona Alibolandi
Feb 25, 2020·Advanced Drug Delivery Reviews·A L B SeynhaeveT L M Ten Hagen
Oct 2, 2020·International Journal of Pharmaceutics·Jiang YuYongjun Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.